Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DBV TechnologiesDBVT -1.73%31 Equity-to-Asset is 0.72 as of Jun. 2026, which is 1% below its 10-year median of 0.73. GuruFocus rates DBVT with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, DBV Technologies ranks better than 55.4% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. DBV Technologies's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $160.50 Mil. DBV Technologies's Total Assets for the quarter that ended in Jun. 2026 was $223.20 Mil.
The historical rank and industry rank for DBV Technologies's Equity-to-Asset or its related term are showing as below:
DBVT'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.06 Med: 0.73 Max: 0.86
Current: 0.72
During the past 13 years, the highest Equity to Asset Ratio of DBV Technologies was 0.86. The lowest was 0.06. And the median was 0.73.
DBVT's Equity-to-Asset is ranked better than 55.4% of 1417
companies
in the Biotechnology industry
Industry Median: 0.68
vs DBVT: 0.72
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
DBV Technologies Equity-to-Asset Related Terms
DBV Technologies Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for DBV Technologies's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBVT vs VRTX, REGN, ALNY: Equity-to-Asset Comparison
For the Biotechnology subindustry, DBV Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where DBV Technologies's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
DBV Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DBV Technologies (DBVT) has a Equity-to-Asset of 0.72 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on DBV Technologies and its competitors. This is near median its historical median of 0.73. Over the past decade, DBV Technologies' Equity-to-Asset has ranged from 0.06 to 0.86. According to the industry distribution chart, DBV Technologies ranks #632 out of 1417 companies in the Biotechnology industry, placing it in the top 44.6%.
Is DBV Technologies' Equity-to-Asset too high?
DBV Technologies' current Equity-to-Asset of 0.72 is near median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.86. The Biotechnology industry median Equity-to-Asset is 0.68. DBV Technologies' value of 0.72 is 5.9% above this industry median. Based on the distribution chart, DBV Technologies ranks #632 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DBV Technologies ranks #632 out of 1417 companies for Equity-to-Asset. This puts DBV Technologies in the upper half of its industry. The industry median Equity-to-Asset is 0.68. DBV Technologies' value of 0.72 is 5.9% above this benchmark. Historically, DBV Technologies' own Equity-to-Asset has ranged from 0.06 to 0.86 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 0.68, DBV Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DBV Technologies's current Equity-to-Asset of 0.72 is 5.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on DBV Technologies and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DBV Technologies's current Equity-to-Asset is 0.72, which is near median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVT) has a current Equity-to-Asset of 0.72. The current Equity-to-Asset is 0.72, which is near median its 10-year median of 0.73 and 5.9% above the Biotechnology industry median of 0.68. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For DBV Technologies (DBVT), the current Equity-to-Asset is 0.72 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score
Get the complete analysis for DBVT
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DBVT has been successfully added to your 
